The Molecular Pathogenesis and Clinical Implications of Hepatocellular Carcinoma

Table 1

Study results of molecular-targeted agents for hepatocellular carcinoma.

Agent	Target	Year	Phase	Patients	CR (%)	PR (%)	SD (%)	RR (%)	PFS (months)	TTP (months)	OS (months)	Authors	Reference number
Sorafenib SHARP study versus placebo	RAF, VEGFR, PDGFR	2008	III	299	0	2.3	71.0	2.3	4.1	5.5	10.7	Llovet et al.	[27]
				303	0	0.7	67.0	0.7	4.9	2.8	7.9
Sorafenib Asia-Pacific study versus placebo		2009	III	150	0	3.3	54.0	3.3	3.5	2.8	6.5	Cheng et al.	[28]
				76	0	1.3	27.6	1.3	3.4	1.4	4.2
Sunitinib	VEGFR, PDGFR	2009	II	37	0	2.7	35.1	2.7	3.7	5.3	8.0	Faivre et al.	[53]
		2009	II	34	0	2.9	50.0	2.9	3.9	4.1	9.8	Zhu et al.	[54]
Brivanib	VEGFR, FGFR	2009	II	55	NR	NR	NR	5.0	NR	2.8	10.0	Raoul et al.	[55]
Erlotinib	EGFR	2005	II	38	0	9.0	50.0	9.0	NR	3.2	13.0	Philip et al.	[56]
Erlotinib + bevacizumab		2009	II	40	0	25.0	38.0	25.0	9.0	NR	15.7	Thomas et al.	[60]
TSU-68	VEGFR, PDGFR, FGFR	2008	I/II	35	2.9	5.7	42.9	8.6	NR	NR	NR	Kanai et al.	[57]
Bevacizumab	VEGF	2009	II	46	2	11.0	NR	13.0	6.9	NR	12.4	Siegel et al.	[58]
Cetuximab	EGF	2007	II	30	0	0.0	NR	0	1.4	NR	9.6	Zhu et al.	[59]

CR: complete response; PR: partial response; SD: stable disease; RR: response rate; PFS: progression-free survival; TTP: time to progression; OS: overall survival; NR: not reported.